Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN5VDB)

Drug Name
ATI-1150 Drug Info
Synonyms SN-38 (Protein Stabilized Nanoparticle, cancer), Azaya; SN-38 (injectable liposomal, Protein Stabilized Nanoparticle), Azaya
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DMN5VDB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting DNA topoisomerase I (TOP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [2]
Topotecan DMP6G8T Central nervous system neoplasm Approved [2]
B-Lactams DMR8YD6 Bacterial infection 1A00-1C4Z Approved [3]
Belotecan hydrocholoride DM3SRJZ Small-cell lung cancer 2C25.Y Approved [4]
Topetecan DMAE6LK Small-cell lung cancer 2C25.Y Approved [5]
Karenitecin DMCRGY4 Lung cancer 2C25.0 Phase 3 [6]
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Exatecan DMCA7FN Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Edotecarin DM3ZL7D Gastric adenocarcinoma 2B72 Phase 3 [9]
Rubitecan DMDWU1S Human immunodeficiency virus infection 1C62 Phase 3 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
4 Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
7 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
8 Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
9 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
10 Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.